Condition: Rhematoid Arthritis · Sponsor: Foundation University Islamabad
1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.
This description comes directly from the study's public registry record.
Dr. Zarafshan Bader, MPhil, MBBS · 0923005177254 · zarafshan.bader@fui.edu.pk
Dr Abida Shaheen, PHD, MBBS, FAIMER FELLOW · abida.scm@stmu.edu.pk
Always discuss trial participation with your own doctor first.
| Shifa International Hospital | Islamabad, Punjab Province, Pakistan | Completed |
| Fauji Foundation Hospital, Rawalpindi | Rawalpindi, Punjab Province, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07388407